NCT01843621View on ClinicalTrials.gov

A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2009

Conditions
Dengue
Interventions
BIOLOGICAL

DEN vaccine F17

The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).

Trial Locations (1)

10400

Department of Pediatrics, Phramongkutklao Hospital, Phayathai

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED